Suppr超能文献

快速且经济高效地检测一大串连续肺癌中的重排。

Rapid and Cost-Efficient Detection of Rearrangements in a Large Consecutive Series of Lung Carcinomas.

机构信息

Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 St.-Petersburg, Russia.

Department of Medical Genetics, St.-Petersburg Pediatric Medical University, 194100 St.-Petersburg, Russia.

出版信息

Int J Mol Sci. 2023 Jun 23;24(13):10530. doi: 10.3390/ijms241310530.

Abstract

-kinase-activating gene rearrangements occur in approximately 1-2% of non-small-cell lung carcinomas (NSCLCs). Their reliable detection requires next-generation sequencing (NGS), while conventional methods, such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) or variant-specific PCR, have significant limitations. We developed an assay that compares the level of RNA transcripts corresponding to 5'- and 3'-end portions of the gene; this test relies on the fact that translocations result in the upregulation of the kinase domain of the gene and, therefore, the 5'/3'-end expression imbalance. The present study included 16,106 consecutive NSCLC patients, 14,449 (89.7%) of whom passed cDNA quality control. The 5'/3'-end unbalanced expression was observed in 184 (1.3%) tumors, 169 of which had a sufficient amount of material for the identification of translocation variants. Variant-specific PCR revealed rearrangements in 155/169 (91.7%) tumors. RNA quality was sufficient for RNA-based NGS in 10 cases, 8 of which carried exceptionally rare or novel ( and ) translocations. We also applied variant-specific PCR for eight common rearrangements in 4680 tumors, which emerged negative upon the 5'/3'-end unbalanced expression test; 33 (0.7%) of these NSCLCs showed fusion. While the combination of the analysis of 5'/3'-end expression imbalance and variant-specific PCR allowed identification of translocations in approximately 2% of consecutive NSCLCs, this estimate approached 120/2361 (5.1%) in /////-negative carcinomas. -rearranged tumors obtained from females, but not males, had a decreased level of expression of thymidylate synthase ( < 0.00001), which is a known predictive marker of the efficacy of pemetrexed. The results of our study provide a viable alternative for testing in facilities that do not have access to NGS due to cost or technical limitations.

摘要

激酶激活基因重排在非小细胞肺癌(NSCLC)中约占 1-2%。其可靠检测需要下一代测序(NGS),而传统方法,如免疫组织化学(IHC)、荧光原位杂交(FISH)或变体特异性 PCR,具有显著的局限性。我们开发了一种比较基因 5'和 3'端 RNA 转录本水平的检测方法;该检测方法依赖于以下事实:易位导致基因激酶结构域的上调,因此 5'/3'端表达失衡。本研究纳入了 16106 例连续 NSCLC 患者,其中 14449 例(89.7%)通过了 cDNA 质量控制。在 184 例(1.3%)肿瘤中观察到 5'/3'端不平衡表达,其中 169 例有足够的材料用于鉴定易位变体。变体特异性 PCR 在 155/169 例(91.7%)肿瘤中发现了 易位。在 10 例肿瘤中 RNA 质量足以进行基于 RNA 的 NGS,其中 8 例携带异常罕见或新型(和)易位。我们还在 4680 例肿瘤中应用变体特异性 PCR 检测 8 种常见的 易位,这些肿瘤在 5'/3'端不平衡表达检测中呈阴性;其中 33 例(0.7%)非小细胞肺癌显示出 融合。虽然 5'/3'端 表达失衡分析与变体特异性 PCR 的结合可在大约 2%的连续 NSCLC 中鉴定出 易位,但在 /////-阴性癌中,这一估计值接近 120/2361(5.1%)。从女性而非男性获得的 易位肿瘤的胸苷酸合成酶表达水平降低(<0.00001),这是培美曲塞疗效的已知预测标志物。我们的研究结果为那些由于成本或技术限制而无法进行 NGS 的机构提供了一种可行的替代 检测方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a151/10342123/cfe4104f52d0/ijms-24-10530-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验